Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study
will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in
Chinese advanced solid tumor patients.